What’s the current market cap for MedCap AB stock?

MedCap AB (MCAP) has a market cap of Skr7.4bn as of June 16, 2026.

What is the P/E ratio for MedCap AB stock?

The price to earnings (P/E) ratio for MedCap AB (MCAP) stock is 33.07 as of June 16, 2026.

Does MedCap AB stock pay dividends?

No, MedCap AB (MCAP) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next MedCap AB dividend payment date?

MedCap AB (MCAP) stock does not pay dividends to its shareholders.

What is the beta indicator for MedCap AB?

MedCap AB (MCAP) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy MedCap AB stock | SkrMCAP Share Price

07:00

09:05

11:15

13:20

15:25

About MedCap AB

MedCap AB, established in 2001 and headquartered in Stockholm, Sweden, is a private equity firm specializing in the acquisition and development of small to medium-sized companies within the life sciences sector. The firm focuses on three primary business areas: MedTech, Assistive Tech, and Specialty Pharma. MedCap's portfolio includes subsidiaries such as Abilia, which operates in assistive technology; Cardiolex, specializing in ECG solutions; and Unimedic, involved in specialty pharmaceuticals. The company primarily targets investments in Northern Europe, aiming to support businesses with international growth potential. MedCap typically acquires majority stakes, providing capital, expertise, and networks to foster long-term development.

Ticker

Skr MCAP

Sector

Health

Primary listing

XSTO

Employees

637

Headquarters

Stockholm, Sweden

Website

medcap.se/en

MedCap AB Metrics

BasicAdvanced

kr 7.4bn

33.07

kr 15.00

0.47

Bulls say / Bears say

Net sales in Q1 2026 rose 13% year-on-year to SEK 556.6 million, supported by 4% organic growth and strategic acquisitions across MedTech, Assistive Tech, and Specialty Pharma portfolios (MedCap Q1 report)

EBITDA margin improved to 22.9% in Q1 2026, up 2.8 percentage points from 20.1% a year earlier, reflecting enhanced operational efficiency across the group (MedCap Q1 report)

Net debt/EBITDA remained low at 0.7x including IFRS 16 (0.2x excl. IFRS 16) as of March 31 2026, preserving ample capacity for further bolt-on acquisitions (MedCap Q1 report)

Q4 2025 EBITA is expected to decline 23% year-on-year to SEK 71 million, driven by significantly lower earnings in the Specialty Pharma business area due to heightened competition in the UK melatonin market (Reuters)

Adjusted EBITA for Q4 2025 is forecast to fall 27% year-on-year, with margins adversely impacted by an unfavorable product mix and inventory write-downs in key subsidiaries (Reuters)

The equity/assets ratio contracted to 57% in Q1 2026 from 64% a year earlier, reflecting increased leverage from contingent consideration liabilities tied to recent acquisitions and potentially constraining financial flexibility (MedCap Q1 report)

Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy Skr MCAP

Skr

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

EBITDA margin improved to 22.9% in Q1 2026, up 2.8 percentage points from 20.1% a year earlier, reflecting enhanced operational efficiency across the group (MedCap Q1 report)

Net debt/EBITDA remained low at 0.7x including IFRS 16 (0.2x excl. IFRS 16) as of March 31 2026, preserving ample capacity for further bolt-on acquisitions (MedCap Q1 report)

Adjusted EBITA for Q4 2025 is forecast to fall 27% year-on-year, with margins adversely impacted by an unfavorable product mix and inventory write-downs in key subsidiaries (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2026.

About MedCap AB

Ticker

Primary listing

Employees

Headquarters

MedCap AB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Skr MCAP

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

MedCap AB/Skr MCAP

About MedCap AB

Ticker

Primary listing

Employees

Headquarters

MedCap AB Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy Skr MCAP

Upcoming events

No upcoming events

What’s the current market cap for MedCap AB stock?

What is the P/E ratio for MedCap AB stock?

Does MedCap AB stock pay dividends?

When is the next MedCap AB dividend payment date?

What is the beta indicator for MedCap AB?

Bulls say / Bears say